共 50 条
- [1] A longitudinal PKPD model describing the static Physician Global Assessment (sPGA) Response to ixekizumab in patients with moderate to severe plaque psoriasisJOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2016, 43 : S37 - S37Choi, Siak LengJackson, KimberleyChigutsa, Emmanuelde Mendizabal, Nieves VelezChua, LaiyiHu, LeijunFriedrich, Stuart
- [2] A PKPD Model Describing the Effect of Ixekizumab on Absolute Psoriasis Area and Severity Index (PASI) score in Patients with Moderate to Severe Plaque PsoriasisJOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2015, 42 : S38 - S38de Mendizabal, Nieves VelezHeathman, MichaelSiak-Leng, ChoiChigutsa, EmmanuelChua, LaiyiFriedrich, StuartHu, LeijunJackson, Kimberley
- [3] Rapid response in PASI, sPGA, and BSA measures for patients with moderate-to-severe plaque psoriasis with ixekizumabJOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (05) : S93 - S93Leonardi, C.Burge, R.See, K.Shrom, D.Guo, J.McKean-Matthews, M.Amato, D.Gallo, G.Gooderham, M.
- [4] An exposure response model to describe the relationship between ixekizumab concentrations and the static Physicians' Global Assessment (sPGA) score and the Psoriasis Area and Severity Index (PASI) in patients with moderate to severe plaque psoriasisJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB235 - AB235Chigutsa, EmmanuelMendizabal, NievesdeChua, LaiyiChoi, Siak LengHu, LeijunFriedrich, StuartJackson, Kimberley
- [5] Efficacy and Safety of Ixekizumab in Pediatric Patients with Moderate-to-Severe Plaque PsoriasisJOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 17 - 17Paller, AmySeyger, MariekeAlejandro Magarinos, GabrielBagel, JerryKeller, StuartCapriles, Claudia RodriguezGallo, GaiaEdson-Heredia, EmilyLi, LingnanXu, WenPapp, Kim
- [6] Early onset of clinical improvement with ixekizumab in patients with moderate-to-severe plaque psoriasisJOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 73 - 74Khatri, S.Amir, Y.Min, M.Goldblum, O.Solotkin, K.Yang, F.Ridenour, T.Lebwohl, M.
- [7] Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and comorbid diabetes mellitusBRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (01) : E31 - E31Egeberg, A.Schaekel, K.Puig, L.Saure, D.Yali Wang, I.Pavo, I.Mahar, P.Schuster, C.Griffiths, C. E. M.
- [8] Static Physicians Global Assessment (sPGA) of 0 or 1 is associated with improved patient reported outcomes in patients with moderate to severe psoriasis in a phase 2 trial of ixekizumabJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB190 - AB190Zhu, BaojinLeonardi, CraigEdson-Heredia, EmilyCameron, GregoryGordon, KennethHeffernan, MichaelBanerjee, SubhashisMaeda-Chubachi, Tomoko
- [9] Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetesFRONTIERS IN MEDICINE, 2023, 9Egeberg, AlexanderMerola, Joseph F.Schaekel, KnutPuig, LuisMahar, Patrick D.Wang, Isabella YaliPavo, ImreSchuster, ChristopherGriffiths, Christopher E. M.
- [10] Sustained Efficacy of Ixekizumab in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Psoriatic ArthritisARTHRITIS & RHEUMATOLOGY, 2016, 68Papp, KimGottlieb, Alice B.Shuler, Catherine L.Burge, Russel T.Cameron, GregoryKerr, LisaMease, Philip J.